Search

Kai Yong Lin

from Bowie, MD
Age ~50
Get Report
Also known as:
Kai Y Lin, Yong Kai Lin, Kaiyong Y Lin, Lin Y Kaiyong, Lin Y Kai
Related to:
Wenyan Lin, 39Chao L Li, 46Zhixiong LinYou LinQin Lin, 58Lin He, 66
Connected to:
Abby C Lin, 44Ai H Lin, 74Aidi Lin, 31Alisa Y Lin, 47Alyssa Lin, 39Amy LinAndrea Lin, 51Angelia Lin, 29Angelica B Lin, 52Anhua A Lin, 51

Kai Lin Phones & Addresses

  • Bowie, MD
  • Landover, MD
  • Waldorf, MD
  • Malden, MA
  • Quincy, MA

Work

Company: Idenix pharmaceuticals, inc. (a wholly owned subsidiary of merck & co.) May 2014 Position: Executive director, biology and translational science (sr. principle scientist)

Education

School / High School: University of Pennsylvania Jan 1994 Specialities: Ph.D. in Biochemistry

Skills

Drug discovery and development • molecular biology • cell biology • biochemistry • virology • oncology

Business Records

Name / Title
Company / Classification
Phones & Addresses
Kai Lin
RUBY BOWL INC

Publications

Us Patents

Hcv Ns3-Ns4A Protease Resistance Mutants

View page
US Patent:
7494660, Feb 24, 2009
Filed:
Oct 27, 2004
Appl. No.:
10/974558
Inventors:
Chao Lin - Winchester MA, US
Kai Lin - Waltham MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
C12N 7/00
C07H 21/04
US Classification:
4242181, 536 231
Abstract:
The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.

Hcv Ns3-Ns4 Protease Resistance Mutants

View page
US Patent:
7884199, Feb 8, 2011
Filed:
Nov 17, 2008
Appl. No.:
12/272425
Inventors:
Chao Lin - Winchester MA, US
Kai Lin - Waltham MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
C07H 23/00
C12N 7/00
C12Q 1/70
US Classification:
536 2371, 4353201, 435 691, 4352351, 435 6
Abstract:
The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.

Compositions For Hcv Treatment

View page
US Patent:
7897565, Mar 1, 2011
Filed:
Dec 20, 2005
Appl. No.:
11/720105
Inventors:
Kai Lin - Waltham MA, US
Beat Weidmann - Winchester MA, US
Assignee:
Novartis AG - Basel
International Classification:
A61K 31/7068
A61K 38/13
US Classification:
514 11, 514 49
Abstract:
The present invention concerns a pharmaceutical combination comprising a) a first agent which is a non-immunosuppressive cyclophilin-binding cyclosporine, e. g. , a compound of formula I and b) a co-agent. Co-agents include, but are not limited to, interferons, a conjugate of interferon, antiviral agents, helicase inhibitors, protease inhibitors, polymerase inhibitors and nucleoside analogs. The instant pharmaceutical combination may be used, e. g. , in treating subjects having a flaviviridae infection, e. g. , a Hepatitis C infection.

Use Of Sanglifehrin In Hcv

View page
US Patent:
20090221598, Sep 3, 2009
Filed:
Jun 15, 2006
Appl. No.:
11/917781
Inventors:
Kai Lin - Waltham MA, US
Beat Weidmann - Winchester MA, US
Kaspar Zimmermann - Oberwil, CH
International Classification:
A61K 31/501
A61P 31/12
US Classification:
51425204
Abstract:
The present invention discloses the use of a cyclophilin-binding compound such as a sanglifehrin for the treatment and prevention of hepatitis C and related diseases such as liver fibrosis, liver cirrhosis and hepatocellular carcinoma.

Hcv Ns3-Ns4 Protease Resistance Mutants

View page
US Patent:
20110086006, Apr 14, 2011
Filed:
Dec 17, 2010
Appl. No.:
12/972175
Inventors:
Chao Lin - Winchester MA, US
Kai Lin - Waltham MA, US
Assignee:
VERTEX PHARMACEUTICALS INCORPORATED - Cambridge MA
International Classification:
A61K 38/21
C07H 21/00
C12N 9/50
C12N 15/63
C12N 5/10
C12N 7/00
C12Q 1/68
C12Q 1/37
C12N 9/99
C07K 5/10
A61K 38/07
A61K 39/29
A61P 37/02
A61P 31/12
A61P 31/14
G06G 7/58
US Classification:
424 855, 536 232, 435219, 4353201, 435325, 4352351, 435 6, 435 23, 435184, 530330, 514 37, 4242281, 424 856, 424 857, 703 11
Abstract:
The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.

Bicyclic Acetyl-Coa Carboxylase Inhibitors And Uses Thereof

View page
US Patent:
20120028969, Feb 2, 2012
Filed:
Jul 25, 2011
Appl. No.:
13/189760
Inventors:
David Weninger BARNES - Cambridge MA, US
Gregory Raymond BEBERNITZ - Cambridge MA, US
Kevin CLAIRMONT - Cambridge MA, US
Scott Louis COHEN - Cambridge MA, US
Robert Edson DAMON - Cambridge MA, US
Robert Francis DAY - Cambridge MA, US
Stephanie Kay DODD - Cambridge MA, US
Christoph GAUL - Basel, CH
Hatice Belgin GULGEZE EFTHYMIOU - Cambridge MA, US
Monish JAIN - Cambridge MA, US
Rajeshri Ganesh KARKI - Cambridge MA, US
Louise Clare KIRMAN - Cambridge MA, US
Kai LIN - Cambridge MA, US
Justin Yik Ching MAO - Cambridge MA, US
Tajesh Jayprakash PATEL - Cambridge MA, US
Brian Kenneth RAYMER - Cambridge MA, US
Liansheng SU - Cambridge MA, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 31/542
A61K 31/5365
A61K 31/5377
A61K 31/4985
A61K 31/47
A61K 31/4245
A61K 31/4184
A61K 31/405
C07D 513/04
C07D 498/04
C07D 413/12
C07D 471/04
C07D 215/00
C07D 235/04
C07D 209/04
A61P 31/12
A61P 3/10
A61P 3/08
A61P 3/04
A61P 3/06
A61P 3/00
C12N 9/99
US Classification:
5142242, 435184, 5142305, 5142352, 514249, 514311, 514364, 514394, 514415, 544 48, 544105, 544144, 544350, 546152, 548143, 5483044, 548469
Abstract:
The present invention provides compounds of formula (I);or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.

Combination Pharmaceutical Agents As Rsv Inhibitors

View page
US Patent:
20220323460, Oct 13, 2022
Filed:
Nov 10, 2020
Appl. No.:
17/094029
Inventors:
- Watertown MA, US
In Jong Kim - Lexington MA, US
Thomas P. Blaisdell - Watertown MA, US
Jianming Yu - Plainsboro NJ, US
Joseph Panarese - Newton MA, US
Kai Lin - Belmont MA, US
Michael H.J. Rhodin - Stow MA, US
Nicole V. McAllister - Groton MA, US
Yat Sun Or - Waltham MA, US
International Classification:
A61K 31/5513
C07D 491/04
C07D 213/12
C07D 213/14
A61K 31/7056
A61K 39/42
A61K 39/395
C07D 403/12
C07K 16/10
C07D 217/14
C07D 243/24
A61K 45/06
C07D 217/12
A61K 31/4439
C07D 498/08
A61P 31/14
Abstract:
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

Combination Pharmaceutical Agents As Rsv Inhibitors

View page
US Patent:
20190192535, Jun 27, 2019
Filed:
Sep 28, 2018
Appl. No.:
16/145768
Inventors:
- Watertown MA, US
In Jong Kim - Lexington MA, US
Thomas P. Blaisdell - Brighton MA, US
Jianming Yu - Plainsboro NJ, US
Joseph Panarese - Malden MA, US
Kai Lin - Belmont MA, US
Michael H.J. Rhodin - Stow MA, US
Nicole V. McAllister - Groton MA, US
Yat Sun Or - Watertown MA, US
International Classification:
A61K 31/5513
A61P 31/14
Abstract:
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
Control profile
Kai Yong Lin from Bowie, MD, age ~50 Get Report